1 March 2023
EMA/CMDh/59494/2023

Report from the CMDh meeting held on 21-22 February 2023

Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures

With a view to simplifying regulatory procedures, the CMDh has agreed an update of the BPG on the processing of renewals in MRP and DCP. The previous approach for generic marketing authorisations with submission of a cover letter and eAF without annexes and a shorter timetable (30 days) will become the standard renewal procedure from now on for all marketing authorisations, regardless of the legal basis. As previously, it is possible for the Member States to request additional documentation, for national legislative reasons. An expanded procedure with an extended timetable (90 days) and full documentation will be applied only in exceptional cases, due to circumstances surrounding the individual marketing authorisation.

The new process will be applicable to all MRP/DCP renewal applications submitted as of the publication of the revised BPG. Ongoing procedures at the time of publication will be finalised according to the previous version of the BPG. For applications submitted before, but not yet started at the time of publication, it will be at the discretion of the RMS to decide whether to apply the new or the old process.

The updated BPG will be published on the CMDh website under "Procedural Guidance > Renewal".

The CMDh also agreed a corresponding update of the cover letter template for renewals. The updated template will be published under "Templates > Renewals".

Further guidance documents will be revised over the coming months to be aligned with the new process.

Impurity chloromethyl isopropyl carbonate (CMIC) in tenofovir disoproxil-containing medicinal products

Following a review of available data including in vitro studies by the Non-clinical Working Party, it has been concluded that the impurity CMIC is considered to be a class 2 mutagenic impurity according to ICH M7.

In the absence of robust *in vivo* data to the contrary, MAHs need to put in place measures (if not already in place) to ensure that levels of CMIC are below the limit of 50 ppm in the active substance.

The CMDh has agreed to publish a letter addressed to MAHs of tenofovir disoproxil-containing medicinal products approved via MRP/DCP or via national procedures with further details on the next steps and timelines for the relevant submissions.

The letter will be published on the CMDh website under "Advice from CMDh".

Position paper common grounds seen for invalidation/ delaying day 0 for variations

The CMDh has agreed an update of its position paper on common grounds seen for invalidation/ delaying day 0 for variations. The document has been updated with the experience gained. Reference to the requirement to provide a dispatch list has been removed and the document has been aligned with the latest updates of the electronic application form (eAF) for variations.

The updated document will be published on the CMDh website under "Procedural Guidance > Variation".

Summary of CMDh activities in 2022

The CMDh has agreed to publish a summary of the main activities carried out by the CMDh and its working groups/working parties in 2022. A list of new and revised CMDh documents published by the CMDh in 2022 is included as an Annex to the document. The document will be published on the CMDh website under "About CMDh > CMDh reports".

CMDh positions following PSUSA procedures for nationally authorised products only

The CMDh, having considered the PSURs on the basis of the PRAC recommendations and the PRAC assessment reports, agreed by consensus on the variation of the marketing authorisations of medicinal products containing the following active substance:

- carbetocin
- ropinirole

Further information regarding the above mentioned PSUSA procedures, including information on the implementation, will be published on the EMA website.

Outcome of PSUR Follow-up procedures

Hydroxychloroquine - DK/H/PSUFU/00001693/202104

The CMDh adopted the outcome of the PSUFU procedure for hydroxychloroquine.

Based on the review of data submitted, the CMDh agreed that concerned MAHs should update the SmPC with regard to hepatotoxicity (update of SmPC section 4.4 and 4.8 and PL section 4), congenital malformations (SmPC section 4.6 and PL section 2) and risk of Hepatitis B virus reactivation (SmPC section 4.4 and PL section 2).

The summary assessment report will be published on the CMDh website under "Pharmacovigilance > PSUR > PSUR Follow-up procedures".

EU Worksharing Articles 45 & 46 of the Paediatric Regulation – Public Assessment Reports

The CMDh has agreed a public assessment report for paediatric studies submitted in accordance with Article 45 of the Paediatric Regulation for:

- Haemophilus influenzae type b vaccine (Hiberix)

The CMDh has also agreed a public assessment report for paediatric studies submitted in accordance with Article 46 of the Paediatric Regulation for:

- Certican (everolimus)

The public assessment reports will be published on the CMDh website under "Paediatric Regulation > Assessment reports".

NEW APPLICATIONS

Mutual Recognition Procedure

Table 1. New applications in Mutual Recognition procedure started in January 2023

Member State	Number of times involved in a procedure as RMS	Number of times involved in a procedure as CMS
Austria	1	3
Belgium		1
Bulgaria		1
Croatia		1
Cyprus		4
Czech Republic	1	4
Denmark	2	4
Estonia	1	
Finland		3
France		4
Germany	7	5
Greece		2
Hungary	2	2
Iceland		4
Ireland		2
Italy		9
Latvia		
Liechtenstein		
Lithuania		1
Luxembourg		1
Malta	1	3
Netherlands	8	3
Norway		5
Poland		5
Portugal	1	5

Member State	Number of times involved in a procedure as RMS	Number of times involved in a procedure as CMS
Romania		3
Slovak Republic		2
Slovenia		
Spain	1	6
Sweden	5	2
United Kingdom (Northern Ireland)		

Decentralised Procedure

Table 2. New applications in Decentralised procedure started in January 2023

Member State	Number of times involved in a procedure as RMS	Number of times involved in a procedure as CMS
Austria	4	16
Belgium	1	14
Bulgaria		16
Croatia	1	8
Cyprus		9
Czech Republic	5	22
Denmark	7	17
Estonia	1	16
Finland	1	16
France	1	20
Germany	24	29
Greece	1	17
Hungary	3	10
Iceland	20	4
Ireland	3	14
Italy		26
Latvia		18
Liechtenstein		
Lithuania	4	19
Luxembourg		16
Malta	7	12
Netherlands	20	8
Norway		24
Poland	2	29
Portugal	1	21
Romania		19
Slovak Republic		22
Slovenia	3	5
Spain		21
Sweden	6	24
United Kingdom (Northern Ireland)		4

Information on the above-mentioned issues can be obtained:

Chair of the CMDh
Mrs Kora Doorduyn-van der Stoep
Medicines Evaluation Board
P.O Box 8275
3503 Utrecht RG
The Netherlands

CMDh Secretariat
Or you could visit the CMDh website at:
E-mail: H-CMDhSecretariat@ema.europa.eu
http://www.hma.eu/cmdh.html